193 related articles for article (PubMed ID: 36280840)
1. Sex-specific changes in triglyceride profiles in liver cirrhosis and hepatitis C virus infection.
Peschel G; Grimm J; Müller M; Höring M; Krautbauer S; Weigand K; Liebisch G; Buechler C
Lipids Health Dis; 2022 Oct; 21(1):106. PubMed ID: 36280840
[TBL] [Abstract][Full Text] [Related]
2. Gender-Specific Differences in Serum Sphingomyelin Species in Patients with Hepatitis C Virus Infection-Sphingomyelin Species Are Related to the Model of End-Stage Liver Disease (MELD) Score in Male Patients.
Peschel G; Weigand K; Grimm J; Müller M; Krautbauer S; Höring M; Liebisch G; Buechler C
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176109
[TBL] [Abstract][Full Text] [Related]
3. Serum Ceramide Species Are Associated with Liver Cirrhosis and Viral Genotype in Patients with Hepatitis C Infection.
Höring M; Peschel G; Grimm J; Krautbauer S; Müller M; Weigand K; Liebisch G; Buechler C
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077197
[TBL] [Abstract][Full Text] [Related]
4. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
5. Serum Galectin-3 in Hepatitis C Virus Infection Declines after Successful Virus Eradication by Direct-Acting Antiviral Therapy.
Weigand K; Peschel G; Grimm J; Müller M; Buechler C
J Gastrointestin Liver Dis; 2022 Dec; 31(4):444-452. PubMed ID: 36535063
[TBL] [Abstract][Full Text] [Related]
6. Rising Lysophosphatidylcholine Levels Post-Hepatitis C Clearance.
Peschel G; Krautbauer S; Weigand K; Grimm J; Höring M; Liebisch G; Müller M; Buechler C
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256273
[TBL] [Abstract][Full Text] [Related]
7. HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV.
Weigand K; Peschel G; Grimm J; Müller M; Höring M; Krautbauer S; Liebisch G; Buechler C
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551908
[No Abstract] [Full Text] [Related]
8. Impact of Chronic Hepatitis C Virus Genotype 1b Infection on Triglyceride Concentration in Serum Lipoprotein Fractions.
Nagano T; Seki N; Tomita Y; Sugita T; Aida Y; Itagaki M; Sutoh S; Abe H; Tsubota A; Aizawa Y
Int J Mol Sci; 2015 Aug; 16(9):20576-94. PubMed ID: 26334270
[TBL] [Abstract][Full Text] [Related]
9. Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy.
Huang R; Rao HY; Yang M; Gao YH; Wang J; Jin Q; Ma DL; Wei L
World J Gastroenterol; 2021 Feb; 27(5):404-415. PubMed ID: 33584072
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C.
Karino Y; Toyota J; Sugawara M; Miyazaki K; Kuwata Y; Yamazaki K; Sato T; Ohmura T; Matsushima T
J Gastroenterol Hepatol; 2003 Apr; 18(4):404-10. PubMed ID: 12653888
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
[TBL] [Abstract][Full Text] [Related]
13. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Iacob S; Cerban R; Pietrareanu C; Ester C; Iacob R; Gheorghe C; Popescu I; Gheorghe L
J Gastrointestin Liver Dis; 2018 Jun; 27(2):139-144. PubMed ID: 29922758
[TBL] [Abstract][Full Text] [Related]
14. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
15. Relationship between genotypes of hepatitis C virus and histopathological manifestations in chronic hepatitis C patients.
Adinolfi LE; Utili R; Andreana A; Tripodi MF; Rosario P; Mormone G; Ragone E; Pasquale G; Ruggiero G
Eur J Gastroenterol Hepatol; 2000 Mar; 12(3):299-304. PubMed ID: 10750650
[TBL] [Abstract][Full Text] [Related]
16. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
[TBL] [Abstract][Full Text] [Related]
17. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
[TBL] [Abstract][Full Text] [Related]
18. [Safety and efficacy of DCV-based DAAs therapy for chronic HCV infection in China].
Wei JY; Lin DN; Wu ZB; Zhu JY; Zhao ZX; Mei YY; Lin CS; Zhang J; Zhang XH
Zhonghua Gan Zang Bing Za Zhi; 2018 Dec; 26(12):933-939. PubMed ID: 30669787
[No Abstract] [Full Text] [Related]
19. Genotype-specific versus pangenotypic regimens in patients infected with hepatitis C virus genotype 1b in real-world settings.
Pabjan P; Brzdęk M; Chrapek M; Dziedzic K; Stępień PM; Paluch K; Garbat A; Błoniarczyk P; Reczko K; Zarębska-Michaluk D
Pol Arch Intern Med; 2021 Nov; 131(11):. PubMed ID: 34565137
[TBL] [Abstract][Full Text] [Related]
20. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
Yuen MF; Liu SH; Seto WK; Mak LY; Corman SL; Hsu DC; Lee MYK; Khan TK; Puenpatom A
Dig Dis Sci; 2021 Apr; 66(4):1315-1326. PubMed ID: 32385703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]